106 related articles for article (PubMed ID: 3373234)
1. Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.
Satomi N; Sakurai A; Haranaka R; Haranaka K
J Biol Response Mod; 1988 Feb; 7(1):54-64. PubMed ID: 3373234
[TBL] [Abstract][Full Text] [Related]
2. Japanese modified traditional Chinese medicines as preventive drugs of the side effects induced by tumor necrosis factor and lipopolysaccharide.
Satomi N; Sakurai A; Iimura F; Haranaka R; Haranaka K
Mol Biother; 1989; 1(3):155-62. PubMed ID: 2604914
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
Haranaka K; Sakurai A; Satomi N
J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
[TBL] [Abstract][Full Text] [Related]
6. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
7. [Effect of 131I-labeled recombinant human tumor necrosis factor-alpha on the nude mice bearing human hepatoma].
Long YH; Li YC; Mi YX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):787-92. PubMed ID: 19950584
[TBL] [Abstract][Full Text] [Related]
8. [An in vitro and in vivo study of antitumor effects of rHTNF-alpha on human ovarian cancer].
Zhao EF; Zhou MQ; Fu CY
Zhonghua Zhong Liu Za Zhi; 1994 Jul; 16(4):273-6. PubMed ID: 7805556
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice.
Buckley NJ; Walther PJ; Das AK; Poulton SH
J Biol Response Mod; 1989 Jun; 8(3):287-96. PubMed ID: 2746299
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on the ultrastructure of the rat lungs after intratumor treatment of Morris hepatoma with rhTNF-alpha and its muteins.
Terlikowski S; Sulkowski S; Sulkowska M; Nowak HF
J Submicrosc Cytol Pathol; 1999 Apr; 31(2):265-72. PubMed ID: 10457612
[TBL] [Abstract][Full Text] [Related]
11. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
[TBL] [Abstract][Full Text] [Related]
12. Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
Hauser GJ; McIntosh JK; Travis WD; Rosenberg SA
Cancer Res; 1990 Jun; 50(12):3503-8. PubMed ID: 2340500
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia against heterotransplanted human prostatic carcinoma and its lymph node metastasis in nude mice.
Hachiya T; Okada K; Sakurai A; Satomi N; Haranaka K
Mol Biother; 1992 Mar; 4(1):34-9. PubMed ID: 1627271
[TBL] [Abstract][Full Text] [Related]
14. Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice.
Zhao E; Zhou M; Fu C; Shen B; Zhang Q; Lian L
Chin Med J (Engl); 1995 Aug; 108(8):571-5. PubMed ID: 7587485
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors.
Hale KK; Smith CG; Baker SL; Vanderslice RW; Squires CH; Gleason TM; Tucker KK; Kohno T; Russell DA
Cytokine; 1995 Jan; 7(1):26-38. PubMed ID: 7749064
[TBL] [Abstract][Full Text] [Related]
16. Selective species specificity of tumor necrosis factor for toxicity in the mouse.
Brouckaert P; Libert C; Everaerdt B; Fiers W
Lymphokine Cytokine Res; 1992 Aug; 11(4):193-6. PubMed ID: 1420597
[TBL] [Abstract][Full Text] [Related]
17. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor.
Zimmerman RJ; Chan A; Leadon SA
Cancer Res; 1989 Apr; 49(7):1644-8. PubMed ID: 2924312
[TBL] [Abstract][Full Text] [Related]
18. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice.
Postma NS; Crommelin DJ; Eling WM; Zuidema J
J Pharmacol Exp Ther; 1999 Jan; 288(1):114-20. PubMed ID: 9862761
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
20. The antitumor effect of intraperitoneal treatment with rhTNF-alpha muteins on Ehrlich ascites tumor growth.
Terlikowski S; Nowak HF
Cancer Biother Radiopharm; 2000 Feb; 15(1):39-46. PubMed ID: 10740651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
